MedTrace Logo

Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease

NCT05034263 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2025-04-06

No results posted yet for this study

Summary

This is an imaging study designed to illuminate the function of the cholinergic system and its association with cognitive skills in people with Parkinson's disease. The hypothesis of this study is that there will be an association between cholinergic terminal density, sex hormones, and cognitive functioning. Participants will receive a PET and MRI scan along with a battery of neurocognitive tests at baseline and again at 18 months follow-up. Hormone levels will be measured at baseline.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Chuan Huang, PhD · Stony Brook Medical Center

  • Carine Maurer, PhD · Stony Brook Medical Center

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-27
Primary Completion
2024-05-27
Completion
2024-05-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034263 on ClinicalTrials.gov